Skip to main content
Glama

Pharma Intel

by io.github.pipeworx-io

Polymarket Edge Tracker

polymarket_edge_tracker
Read-onlyIdempotent

Edge persistence and decay telemetry built from daily polymarket_edges snapshots. Answers "how long has this edge existed and is it shrinking?" — a fresh wide edge and a 3-week-old wide edge are different trades (the latter is wide for a reason nobody is willing to take). Args: days (lookback, default 14, max 30), window (snapshot family, default "1wk"). RESPONSE: tracked[] = every opportunity in the LATEST snapshot with its full edge_pp_net time-series across prior snapshots, first_seen, trend (new | widening | stable | decaying) and decay_pp_per_day (both computed on |edge_pp_net| — the value itself is signed by trade direction, negative = SELL YES); expired[] = opportunities that appeared in earlier snapshots but are GONE from the latest (closed, resolved, or arbed away) with their lifespan_days — the median lifespan is your competition clock; snapshot_dates[] = which days actually have data (snapshots are written when polymarket_edges runs on a cache-miss, so gaps mean nobody scanned that day). LIMITS: history depth is bounded by the 60-day snapshot TTL and starts from when snapshotting was enabled; decay numbers come from daily closes of edge_pp_net (net of default slippage), not intraday.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
daysNoLookback in days (default 14, clamp 2-30).
windowNoWhich polymarket_edges window family to read snapshots for: 24hr | 1wk | 1mo (default 1wk).

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Added
  2. Removed
  3. Added

TDQS

A4.6/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

The description extensively explains behavior beyond annotations: it reads from daily snapshots, computes time-series, trend, decay rate, and expired opportunities. It also clarifies that decay numbers come from daily closes, not intraday. No contradictions with annotations (readOnlyHint, etc.).

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is lengthier but well-structured: starts with purpose, then parameters, then detailed response format, then limits. Every sentence adds value, though some redundancy could be trimmed. It is front-loaded with the key question.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given the complexity of time-series analysis and no output schema, the description completely explains the response structure (tracked, expired, snapshot_dates) and limitations (TTL, snapshot start). Provides all necessary context for an agent to use the tool correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Both parameters have schema descriptions, but the tool description adds context: specifies defaults (days=14, window='1wk'), explains 'window' as a snapshot family, and lists options. This adds meaning beyond the schema alone.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states the tool provides edge persistence and decay telemetry from daily polymarket_edges snapshots, answering a specific question about edge duration and shrinkage. The verb is implied as 'track' and the resource is well-defined, distinguishing it from siblings like polymarket_edges.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly frames the tool around answering 'how long has this edge existed and is it shrinking?' with an example contrasting fresh vs old edges. It provides context on when the tool is useful but does not mention alternatives or when not to use it. The LIMITS section adds clarity on history depth.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Pharma Intel toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A4.1/5.0
Disambiguation5/5

Every tool has a clearly distinct purpose, even within the same domain (e.g., ask_pipeworx vs ask_pipeworx_grounded vs ask_pipeworx_beta are differentiated by groundedness/beta status; polymarket_edges vs polymarket_arbitrage vs polymarket_fill_risk each target discovery vs arbitrage vs execution risk). The descriptions are highly detailed, eliminating ambiguity about when to use each.

Naming Consistency4/5

All tool names use snake_case consistently, and most follow a verb-first pattern (ask_, compare_, discover_, search_, validate_), but a few are noun-first (entity_profile, polymarket_edges, recent_alerts). The style is readable and predictable, though not perfectly uniform in the verb_noun convention.

Tool Count2/5

With 37 tools, the server is heavily over-scoped, especially given the 'Pharma Intel' name that suggests a focused pharma domain. Many tools are general-purpose (prediction markets, memory, subscription management, feedback) unrelated to the server's apparent purpose, making it feel like a grab bag rather than a cohesive set.

Completeness4/5

The pharma-specific tools cover drug profiles, safety, pipeline scans, catalysts, indication landscapes, and sponsor diligence – a solid lifecycle coverage. The broader data/query/prediction-market tools also feel complete for their respective sub-domains. The only minor gaps are niche operations (e.g., updating a subscription), but these are not critical to the core workflows.

Resources